Identification and evaluation of a novel glucokinase allosteric activator in target cells and animal model of type 2 diabetes

被引：0
|
作者：
Nagata, Y
Sasaki, K
Hosaka, H
Ooyama, S
Kadotani, A
Goto, H
Futamura, M
Nishimura, T
Iino, T
Bamba, M
Watanabe, H
Suzuki, J
Li, ZH
Moller, DE
Zhang, BB
Eiki, JI
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 50 条
  • [31] Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus
    Wang, Yuming
    Su, Xiaofei
    Zhang, Wenli
    Zhou, Yunting
    Zhou, Xiao
    Yang, Wei
    Li, Huiqin
    Ma, Jianhua
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2023, 2023
  • [32] Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus
    Xu, Jiayi
    Lin, Songnian
    Myers, Robert W.
    Addona, George
    Berger, Joel P.
    Campbell, Brian
    Chen, Hsuan-Shen
    Chen, Zhesheng
    Eiermann, George J.
    Elowe, Nadine H.
    Farrer, Brian T.
    Feng, Wen
    Fu, Qinghong
    Kats-Kagan, Roman
    Kavana, Michael
    Malkani, Sunita
    McMasters, Daniel R.
    Mitra, Kaushik
    Pachanski, Michele J.
    Tong, Xinchun
    Trujillo, Maria E.
    Xu, Libo
    Zhang, Bei
    Zhang, Fengqi
    Zhang, Rui
    Parmee, Emma R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (09) : 2069 - 2073
  • [33] Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus
    Fujieda, Hiroki
    Kogami, Masakazu
    Sakairi, Masao
    Kato, Noriyasu
    Makino, Mitsuhiro
    Takahashi, Naoki
    Miyazawa, Toshiyuki
    Harada, Satoko
    Yamashita, Tokuyuki
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 156 : 269 - 294
  • [34] Type 2 diabetes: Pharmacological intervention in an animal model
    Russell, JC
    DIABETES AND CARDIOVASCULAR DISEASE: ETIOLOGY, TREATMENT, AND OUTCOMES, 2001, 498 : 295 - 302
  • [35] Clinical validation of the dual-modes of action of glucokinase activator HMS5552 for type 2 diabetes
    Chen, Li
    Zhang, Yi
    Jin, Xiaowei
    Li, Yongguo
    Leng, Yin
    Li, Xuening
    Gao, Xin
    Li, Xiaoying
    Zhu, Dalong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 : 6 - 6
  • [36] A Novel Animal Model in Diabetes: Regeneration of β cells in the Axolotl Salamander
    Sorensen, Pernille L.
    Dittrich, Anita L.
    Lauridsen, Henrik L.
    FASEB JOURNAL, 2022, 36
  • [37] Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study
    Jiang, Yu
    Wang, Luyao
    Dong, Zhenhua
    Xia, Baotian
    Pang, Shuguang
    JOURNAL OF DIABETES, 2024, 16 (06)
  • [38] LY2599506, a Novel Glucokinase Activator (GKA), Improves Fasting and Postprandial Glucose in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bue-Valleskey, Juliana M.
    Schneck, Karen B.
    Sinha, Vikram P.
    Wondmagegnehu, Eshetu T.
    Kapitza, Christoph
    Miller, Jeffrey W.
    DIABETES, 2011, 60 : A272 - A272
  • [39] A novel large animal model of Type 2 Diabetes: The nicotinamide and streptozotocin treated Gottingen minipig
    Larsen, MO
    Rolin, B
    Carr, RD
    Svendsen, O
    DIABETOLOGIA, 2000, 43 : A131 - A131
  • [40] Decreased residual insulin secretory capacity in a novel large animal model of type 2 diabetes
    Rolin, B
    Wilken, M
    Carr, RD
    Larsen, MO
    DIABETOLOGIA, 2001, 44 : A149 - A149
12345